Biosyent Inc. (RX)
TSX Venture Exchange · Canada · prices in CAD · close of 22 Oct 2026
Key indicators
| Last close | CAD 16.95 |
|---|---|
| 52-week range | 10.65 – 17.50 |
| Return, 1 month / 3 months | −3.1% / +17.0% |
| Return, 1 year / 3 years | +54.4% / +123.0% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 32.4% |
| Worst drawdown (1 year) | -13.2% |
| Average daily value traded | 0.18M CAD |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BioSyent Inc. is a Canadian specialty pharmaceutical company based in Mississauga, Ontario. It acquires, licenses and markets prescription and over-the-counter healthcare products, often in niche therapeutic areas, through its BioSyent Pharma business. Its product range includes iron supplements and oral care products sold to pharmacies, healthcare professionals and patients, mainly in Canada. The company also has a pharmaceutical ingredients division that supplies active ingredients to other manufacturers.
The shares are listed on the TSX Venture Exchange in Canada under the code RX, and the price on this page is in Canadian dollars (CAD). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Biosyent Inc. (RX) trades on the TSX Venture Exchange in Canada. It last closed at CAD 16.95 on 22 October 2026.
Its price-based Market X-Ray is 83 out of 100 (a strong price profile), ranking 49 of 1,501 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 54.4% and over the last three months it rose 17.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on TSX Venture Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 88 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 15.1% | ||
| From 52-week high | -3.1% | ||
| Momentum | 84 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 17.0% | ||
| 6-month return | 13.8% | ||
| 12-month return, skipping the last month | 59.3% | ||
| Stability (higher is calmer) | 94 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -13.2% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 0.18M CAD | ||
| Zero-volume days | 3.3% | ||
| Income | 29 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.8% |
|---|---|
| 1 month | −3.1% |
| 3 months | +17.0% |
| 6 months | +13.8% |
| 1 year | +54.4% |
| 3 years | +123.0% |
| 5 years | +163.8% |
Signals
| 50-day / 200-day average | 16.02 / 14.72 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.51 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 31 Aug 2026 | CAD 0.0550 |
| 29 May 2026 | CAD 0.0550 |
| 27 Feb 2026 | CAD 0.0550 |
| 28 Nov 2025 | CAD 0.0500 |
| 29 Aug 2025 | CAD 0.0500 |
| 30 May 2025 | CAD 0.0500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on TSX Venture Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.